<DOC>
	<DOCNO>NCT00305942</DOCNO>
	<brief_summary>This propose phase II trial investigate combination topotecan/carboplatin first-line treatment patient extensive-stage SCLC . Topotecan/platinum regimens emerge common treatment patient extensive-stage disease . This trial one first clinical trial evaluate combination weekly topotecan carboplatin first-line treatment extensive-stage SCLC .</brief_summary>
	<brief_title>Topotecan Carboplatin First-Line Treatment Patients With Extensive Stage Small Cell Lung Cancer</brief_title>
	<detailed_description>Eligible patient receive treatment carboplatin topotecan . Topotecan 4mg/m2 IV day 1 , 8 . Carboplatin AUC=5 IV day 1 . - Cycles repeat every 21 day &gt; 4 cycle topotecan carboplatin ( maximum 6 course ) . Restaging study perform every 2 cycle ( 6 week . )</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Small Cell</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>Patients must confirm small cell lung cancer extensive stage disease . This include patient stage IIIB IV disease . Patients small cell histology eligible . Large neuroendocrine mixed small cell nonsmall cell histology eligible . Patients must measurable evaluable disease . ECOG performance status 0 1 . Patients must adequate bone marrow , liver kidney function The patient may previous chemotherapy . Patients must able understand nature study give write informed consent . Patients limited stage disease . This include IA , IB , IIA , IIB , IIIA . Age &lt; 18 year old . History prior malignancy within three year exception skin cancer ( exclude melanoma ) , cervical carcinoma situ , situ breast carcinoma stage A/B prostate cancer . Female patient pregnant breast feed History acute myocardial infarction stroke within 6 month . Uncontrolled hypertension , unstable angina , New York Heart Association grade II great CHF , serious cardiac arrhythmia require medication , grade II great peripheral vascular disease . Patients receive investigational drug within 28 day . Patients CNS involvement ( brain meningeal ) . The single exception patient previously treat brain metastasis radiation therapy , surgical excision evidence active residual metastasis brain MRI time study entry . Patients large neuroendocrine tumor mix small cell nonsmall cell histology</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Lung Cancer</keyword>
	<keyword>Carcinoma , Small Cell</keyword>
</DOC>